REVIEW article
Front. Cardiovasc. Med.
Sec. Pediatric Cardiology
The Role of Glucose Metabolic Reprogramming in Myocard itis and Advances in Therapeutic Strategies
1. Shandong First Medical University, Jinan, China
2. Shandong Provincial Hospital, Jinan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract
Myocarditis is a heterogeneous inflammatory heart disease most co mmonly triggered by viral infections, such as Coxsackievirus B3 (C VB3), and may progress to dilated cardiomyopathy (DCM) and hear t failure. Growing evidence indicates that glucose metabolic reprogr amming in cardiomyocytes and infiltrating immune cells plays a piv otal role in the initiation and progression of myocarditis. Under phy siological conditions, the adult heart primarily relies on fatty acid β-oxidation for energy production, whereas glucose oxidation serve s a supplementary role. In contrast, myocarditis is characterized by a metabolic shift from oxidative phosphorylation toward enhanced a erobic glycolysis, known as the Warburg effect. This shift results in reduced ATP efficiency, lactate accumulation, excessive reactive ox ygen species production, and amplification of inflammatory response s, thereby establishing a self-sustaining immunometabolic vicious cy cle. This review summarizes glucose metabolism in the normal heart an d highlights the features and regulatory mechanisms of glucose met abolic reprogramming in myocarditis, including the HIF-1α/mTOR axis, NRF2-mediated pentose phosphate pathway, IRG1/itaconate axi s, and PGK1. We also discuss emerging therapeutic strategies target ing glucose metabolism, as well as current challenges in clinical tra nslation. Advances in multi-omics technologies may facilitate the de velopment of precise metabolic interventions for myocarditis.
Summary
Keywords
Glucose, Glycolysis, Immunometabolism, metabolic, Myocarditis, regulatory mechanisms, reprogramming, therapeutic targets
Received
06 January 2026
Accepted
09 February 2026
Copyright
© 2026 Liu and Han. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Bo Han
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.